U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) A... ( TOKYO and WOODCLIFF LAKE N.J. Dec...)

U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing

Date:12/27/2007

TOKYO and WOODCLIFF LAKE, N.J., Dec. 27 /PRNewswire/ --- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) (collectively "Eisai") filed a lawsuit in August 2006 against Mutual Pharmaceutical Co., Inc. and United Research Laboratories, Inc. (collectively "Mutual") claiming that its submission of an abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) for Aricept ODT(R) (donepezil hydrochloride orally disintegrating tablets) would infringe Eisai's composition of matter patent.

On December 20, 2007 (U.S. EST), the U.S. District Court for the District of New Jersey issued a ruling dismissing the lawsuit against Mutual on the procedural grounds that there is no case or controversy between the parties, because Mutual did not make a certification challenging the patent and does not yet have FDA approval to market its product. The Court recognized that Mutual is required, by a stipulation entered between the parties and signed by the Court, to give Eisai 45 days' notice of any launch of a generic version of Aricept ODT(R), and Eisai may during that 45-day period bring an action against Mutual for patent infringement and seek injunctive relief against Mutual's sales of any such product. Therefore, Mutual cannot market the generic version of Aricept ODT(R) immediately.

The Court did not address the substantive merits of Eisai's infringement action against Mutual. Eisai believes that its donepezil composition of matter patent is valid and enforceable until its expiration date of November 25, 2010, and that Mutual would clearly infringe its donepezil composition of matter patent if Mutual were to launch a generic version of Aricept ODT(R) in the United States prior to the expiration. Eisai intends to vigorously enforce and defend that patent.

The Court's ruling has no impact on Eisai's ongoing infringement action against T
'/>"/>

SOURCE Eisai Co., Ltd.; Eisai Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
5. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
6. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
7. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
8. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
9. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
10. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
11. Scientists Using Social Media to Inform Lab Purchasing Decisions

Post Your Comments:

(Date:2/9/2010)... DIEGO , Feb. 9 Ardea ... Felix J. Baker , Ph.D., has been appointed ... a managing partner of Baker Bros. Advisors, LLC, the ... Investments, Ardea,s largest shareholder. ,, "Ardea,s impressive accomplishments ... so I am pleased to join the Board of ...

(Date:2/9/2010)... , February 9 ,Agendia, a ... that,it has received the Clinical Laboratory Permit from ... The New York State permit allows ... FDA-cleared breast cancer recurrence,test. ,, ... obtained all major U.S. clinical,laboratory licenses. In addition, ...

(Date:2/8/2010)... /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE Alternext: TPI), ... based in Chengdu, China ,today announced fiscal results ... . , , -- Q2 2010 ... 24.8% to $2.6 ... basis, -- Cash and Equivalents of ...

(Date:2/8/2010)... Biocell Center announced today its further ... the Society for Maternal-Fetal Medicine,s (SMFM) annual meeting. ... and Ob/Gyn doctors worldwide for several years," said ... Corporation. "We understand the effects that high-risk pregnancy ... are hoping to inform women undergoing amniocentesis that ...

[0] Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors [0] Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists [0] Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results [0] Biocell Center Furthers Its Commitment to Maternal-Fetal Medicine

... BOSTON, May 15 Surface Logix today announced that ... his current position,to pursue other interests. Mr. Mahoney will ... future. Steven Gillis,Ph.D., Managing Director at ARCH Venture Partners ... CEO is appointed., "The Board, shareholders and employees ...

... ARAY ), a global leader in the field ... officer, Euan S.,Thomson, Ph.D., is scheduled to present at ... in New York City, on Thursday, May,22, 2008 at ... webcast of the presentation will be available online from ...

... - IND for liquid formulation, NGX-1998, expected to be opened and, ... dermal patch, NGX-4010, in PHN expected in second half ... ... peripheral neuropathic pain, SAN MATEO, Calif., May 15 NeurogesX, Inc.,(Nasdaq: ...

Other Biology Technology:Surface Logix Announces Executive Management Changes 2 Accuray Incorporated's CEO to Speak at CitiGroup Healthcare Conference 2 NeurogesX Reports First Quarter 2008 Results 2 NeurogesX Reports First Quarter 2008 Results 3 NeurogesX Reports First Quarter 2008 Results 4 NeurogesX Reports First Quarter 2008 Results 5 NeurogesX Reports First Quarter 2008 Results 6 NeurogesX Reports First Quarter 2008 Results 7

Surface Logix Announces Executive Management Changes Accuray Incorporated's CEO to Speak at CitiGroup Healthcare Conference NeurogesX Reports First Quarter 2008 Results

(Date:2/5/2010)... realm of renewable energy could present major obstacles for ... based on carbon resources, according to a report in ... Jack Reardon of the Department of Management & Economics, ... how the transition from carbon to renewable proceeds will ... are listened to in the process. He suggests that ...

(Date:2/5/2010)... , Jan. 26 The ... DigitalPersona, Inc., a leader in fingerprint identity and ... component of Criminal Justice Information System (CJIS) mandates. ... City of Winter Park employs approximately 550 ... City chose DigitalPersona ® Pro and DigitalPersona® ...

(Date:2/5/2010)... - The Wiley Interdisciplinary Reviews (WIREs), the pioneering new ... three of the most prestigious awards in scholarly publishing ... Awards for Professional & Scholarly Excellence (PROSE Awards) named ... Hawkins Award, the association,s top prize, established in 1976 ... the arts and sciences. , The WIREs join ...

Breaking Biology News(10 mins):Renewable oil companies 2 City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance 2 City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance 3 City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance 4 WIREs win 3 prizes at the PROSE awards 2 Its a gas 3A New discovery may lead to heartier high yielding plants 10847 1 Its a gas 3A New discovery may lead to heartier high yielding plants 10847 2 Three Month Supply Lowers Drug Costs 61851 1 Three Month Supply Lowers Drug Costs 61851 2 554 000 in Massachusetts Struggle to Put Food on the Table 61847 1 554 000 in Massachusetts Struggle to Put Food on the Table 61847 2 554 000 in Massachusetts Struggle to Put Food on the Table 61847 3 554 000 in Massachusetts Struggle to Put Food on the Table 61847 4

[0] Renewable oil companies [0] City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance [0] WIREs win 3 prizes at the PROSE awards

... of Parkinson,s disease is tremor in patients. A group ... have succeeded in demonstrating the mechanisms which cause the ... brain drive the tremor. This discovery supports Tass, research ... A new deep brain pacemaker is to bring cells ...

... Arlington, VA (July 10, 2008) A third of ... according to the first-ever comprehensive global assessment to determine ... today by Science Express . , Leading ... Assessment (GMSA) a joint initiative of the International ...

... Mass., July 10, 2008 -- Thomas E. Smith, associate ... a $217,710 three-year grant by the National Cancer Institute ... Methods for the Synthesis of Pyran-Based Anticancer Natural Products." ... new methods that will allow for the efficient preparation ...

Other Biology News:'Cross fire' from the brain makes patients tremble 2 1/3 of reef-building corals face extinction 2 1/3 of reef-building corals face extinction 3 1/3 of reef-building corals face extinction 4

'Cross fire' from the brain makes patients tremble 1/3 of reef-building corals face extinction National Institutes of Health award Williams professor $217,710 research grant

... SeeDNA co-precipitant, 250 ul ... color ensures easy pellet ... acid recovery.Chemically inert, compatible ... applications.Simple 5-minute protocol. Category: ...

EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....

Recombinant Mouse sTNF RII/TNFRSF1B...

Mouse Wnt-11 Affinity Purified Polyclonal Ab...

Biology Products:

SeeDNA co-precipitant from GE Healthcare, formerly Amersham Biosciences EDTA, 0.5 M solution from GE Healthcare, formerly Amersham Biosciences Mouse sTNF RII / TNFRSF1B from R&D Systems Goat Anti-Mouse Wnt-11 Polyclonal Antibodies, from R&D Systems

U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) A...( TOKYO and WOODCLIFF LAKE N.J. Dec...)